Table A5.

Example application of HPV-FRAME guidelines to Lin et al., 2016 [50].

Inputs	Reported? (Y/N)	Report by Age? (Y/N)	Comments
MSM-specific disease burden	Y	Y	Incidence rates by age derived from registries combined with population attributable fractions and relative risks
HIV prevalence	Y	Y	Split by diagnosed and undiagnosed
Time from HPV infection to cancer	Y	N	Natural history model for anal cancer giving rate of progression to cancer precursors and cancer. Proportionate outcomes for other cancers
Vaccine coverage	Y	Y	Age bands 16–25, 16–30, 16–35, 16-40y, 50% among GUM attenders (16.7% of all MSM)
Prior exposure	Y	Y (implicitly)	Estimated by transmission-dynamic model

	Reported? (Y/N)	Report by Age (Y/N)	Report as calibration or validation target? (Y/N)	Comments
Reduction in disease incidence over time	Y	Y	Y (provided post-vaccine data are available)	Separate projections of annual diagnoses of anogenital warts and cancers over time
Impact assessment by disease outcome	Y	N	N	Reported by age for anal cancer and warts; reported as totals for other cancers. Cost-effectiveness analyses only provided for composite outcome measures

GUM: genitourinary medicine clinics; PP: per protocol; N: no; Y: yes.

N: no; Y: yes.